SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ZymoGenetics ZGEN
An SI Board Since February 2002
Posts SubjectMarks Bans Symbol
210 12 0 ZGEN
Emcee:  Mike McFarland Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
160Ah, I did miss something by not looking before November, OK. Took a while for thtuck-2/12/2009
159sec.govDewDiligence_on_SI-2/12/2009
158I had to go out before I could sniff around or listen to the CC. Now that I'tuck-2/12/2009
157<i>Apparently analysts hadn't updated their models for the November paDewDiligence_on_SI-2/11/2009
156Consensus was for a 47 cent loss here on revenues of $12 million. This a huge btuck-2/11/2009
155Nice deal—good partner.DewDiligence_on_SI-1/12/2009
154BMS inks deal for PEG-Interferon Lambda: >>12-Jan-2009 Entry into a Matetuck-1/12/2009
153[Human interferon-lambda3 is a potent member of the type III interferon family] tuck-11/8/2008
152At least for 2008 they don't expect much - $7M but in time I'm sure theyidos-11/7/2008
151Becoming price competitive is the first right move zgen has made. Too bad they drkrw-11/7/2008
150King's Thrombin-JMI sales were $67M in Q3. ZGEN is reducing Recothrom's idos-11/7/2008
149Meanwhile atacicept stumbles a bit, causing ZGEN to firesale and test all time ltuck-10/27/2008
148OMRI -Not as bad as it looked, trial resume with no modifications: UPDATE 1- Omidos-10/27/2008
147<b>ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Canceidos-10/22/2008
146[Immune activation in advanced cancer patients treated with recombinant IL-21] tuck-10/19/2008
145This rebleeding case will at best cost OMRI a few months delay to the market butidos-10/9/2008
144A day later, a case of post-operative bleeding stops that same trial! Message 2tuck-10/9/2008
143OT - OMRI Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiidos-10/8/2008
142Semi OT - OMRI An article published today in a local newspaper claims that JNJ hidos-8/18/2008
141KG reported Thrombin-JMI net sales totaled of $64M during 2Q08, compared to $65Midos-8/7/2008
140It’s not ever going to be a big-selling drug, IMHO.DewDiligence_on_SI-8/5/2008
139Considering that Recothrom was approved in mid- January, a 40% quarter over quartuck-8/5/2008
138[IFN-alpha and IFN-lambda differ in their antiproliferative effects and durationtuck-8/3/2008
137Deerfield has a good thing going. They've done at least a few of these dealsrkrw-7/1/2008
136>>ZymoGenetics Secures $100 Million Funding Commitment SEATTLE--(BUSINESStuck-7/1/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News